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The outlook for patients with advanced ovarian cancer who
experience disease relapse following treatment with platinum-
based chemotherapy is poor. As well as searching for more
effective cytotoxic chemotherapy regimens recent attention
has also focused on identifying those agents which have
minimal toxicity but still retain clinical activity. In response
to the discovery of oestrogen and progesterone receptors on
ovarian cancer cells (Holt et al., 1979; Rendina et al., 1982;
Ford et al., 1983; Willocks et al., 1983) hormonal therapy
with either tamoxifen or progestagins has been undertaken
by many investigators. However to date therapeutic results
have been disappointing with response rates to tamoxifen
ranging from 0% to 10% (Shirey et al., 1985; Slevin et al.,
1986; Weiner et al., 1987; Osborne et al., 1988) and response
rates to various progestagins ranging from 0% to 20% (Slot-
man & Rao, 1988).
Androgen receptors have now also been identified on
ovarian cancer cells (Hamilton et al., 1981) suggesting that
therapy with androgen antagonists may have therapeutic
potential. Cyproterone acetate is a steroidal antiandrogen
which blocks the androgen receptor but in addition has
potent progestational and antigonadotropic effects (Neu-
mann, 1982). In 1989 Alma et al. reported that culture of an
ovarian cancer cell line exhibiting androgen receptors with
10-5 M cyproterone acetate for 24 h resulted in the accumula-
tion of 94% of cells in the GO/GI phase of the cell cycle. The
same investigators also reported the effect of cyproterone
acetate 150 mg per day for 1 week in five patients with
advanced ovarian cancer in relapse after several chemo-
therapy regimens including cisplatin. Tumour proliferative
activity as assessed by the thymidine labelling index of malig-
nant ascitic cells was assessed prior to and following the 1
week of therapy. All patients showed a reduction in thymi-
dine labelling index with post treatment values ranging from
40% to 80% of pretreatment values suggesting that cyproter-
one may at least have some cytostatic effect in vivo. However
to date there are no clinical studies reporting the outcome of
long term therapy and the current study was designed to
further assess the therapeutic potential of cyproterone acetate
in refractory ovarian cancer patients.
Fifty-six patients with advanced ovarian cancer either
refractory to or relapsing after platinum-based chemotherapy
and with a life expectancy of greater than 2 months were
treated. In addition six patients considered too frail for
platinum-based chemotherapy were also treated. Standard
WHO criteria were used to assess response and toxicity. Only
patients with no radiological change in assessable disease
were classified as static disease. Patients with overt or inci-
pient bowel obstruction or with renal failure were excluded
from the study. Table I demonstrates the patient and tumour
characteristics.
Treatment consisted of continuous oral cyproterone ace-
tate 100 mg three times daily. Treatment was only stopped
for progression of disease or toxicity. The median duration
of treatment was 10 weeks.
Details of tumour response and durations of response or
static disease status are summarised in Table II. Fifty-eight
patients are evaluable for response. Four patients (6.8%), all
with serous or mucinous cystadenocarcinomas, experienced
partial responses (PR) for 2.5, 3, 17 + and 18 + months.
Two of the four responding patients had not received prior
platinum-containing chemotherapy due to frailty. One of
these received cyproterone acetate immediately after progres-
sing on chlorambucil and the other had also progressed on
chlorambucil having had a complete remission of disease on
chlorambucil 3 years earlier. Of the other two responding
patients one, who achieved a PR for 17 + months, was
treated immediately after failing to respond to carboplatin
having experienced a complete remission on cisplatin 5 years
previously. The other, who achieved a PR for 18 + months,
was in relapse 2.5 years after achieving a complete remission
with cisplatin. In addition two of seven patients with well
differentiated tumours responded compared to one of 25 and
0 of 22 patients with moderately and poorly differentiated
tumours respectively. In the other responding patient tumour
grade was unknown.
A further eight patients (13.8%) demonstrated static
disease (SD) for 2 to 11 months before experiencing further
Table I Patient characteristics
No. of patients
- prior platinum
- previously untreated (due to age or frailty)
Median age
Median no. previous chemotherapy regimens
Mean Karnofsky Performance Status
Stage at diagnosis (no. of patients):
I
II
III
IV
Unknown
Histological grade (no. of patients):
well differentiated
moderately differentiated
poorly differentiated
undifferentiated
unknown
Histological type (no. of patients):
serous
mucinous
clear cell
endometrioid
unclassified adenocarcinoma
undifferentiated
unknown
62
56
6
63
2
83%
6
38
9
8
7
25
22
1
7
35
6
4
4
9
1
3
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Table II Tumour responses
Response Response durations (months)
Partial response (PR) 4 2.5, 3, 8 +, 13 +
Static disease (SD) 8 2, 3, 3, 4, 4, 6, 6, 11
Progressive disease (PD) 46
Not evaluable (NE) 4
62
disease progression. Two of these eight patients had endo-
metrioid tumours. Forty-six patients had progressive disease
and four patients were not evaluable for response due to
early toxicity (two patients), suicide (one patient) and
unassessable disease at commencement of therapy (one
patient).
Toxicity was generally minimal, but necessitated cessation
of treatment in four patients. Four patients experienced
malaise on commencing therapy and in two patients this
toxicity was severe enough to discontinue therapy. One of
these patients was also receiving increasing doses of mor-
phine MST at the time of experiencing malaise which may
have been a contributory factor. One patient noticed a mild
erythematous rash for 2 days when commencing therapy
which resolved spontaneously without altering therapy. Three
patients experienced transient mild diarrhoea. Abdominal
malignant disease may have contributed in part to nausea
experienced by two patients and to the epigastric discomfort
experienced by three patients. Potentially the most serious
toxicity was the development of a deep venous thrombosis
12 days after commencing treatment in one patient which
resolved spontaneously when treatment was stopped. Ano-
ther patient developed a pulmonary embolus in the setting of
progressive disease 2 months after therapy was commenced
in the presence of massive abdominal malignant disease.
This study has demonstrated for the first time that the
antiandrogen cyproterone acetate has clinical activity in
ovarian cancer. The response rate of 6.9% is low but most
patients had been extensively pretreated and is similar to that
achieved in many studies of other hormonal therapy in this
extensively pretreated patients (Slotman & Rao, 1988). How-
ever no patients experienced a response who had relapsed
disease or disease refractory to platinum-based chemotherapy
within 2 years of first diagnosis. Two of the responding
patients were from the group of six patients who had not
received prior platinum. The two patients responding who
had received prior platinum appeared to have less aggressive
disease than the average patient with advanced ovarian
cancer. One had achieved a complete remission 5 years ear-
lier with cisplatin, although was given cyproterone acetate
after failing to respond to carboplatin, and the other was in
relapse after attaining a complete remission to cisplatin 2.5
years earlier. In addition two of seven patients with well-
differentiated tumours responded compared to one of 25 and
0 of 22 patients with moderately and poorly differentiated
tumours respectively. Patients with more differentiated
tumours have also been shown to respond better to progest-
agin therapy. In 1982 Rendina et al. reported a 55% res-
ponse rate in 33 patients with endometrioid tumours, of
which 79% were well-differentiated. In this study two of four
patients with endometrioid tumours experienced disease
stabilisation.
Despite poor response rates, hormone therapy of refrac-
tory advanced ovarian cancer has long been popular due to
its low toxicity. In the case of the progestagins there may
even be beneficial effects of increase in appetite and weight
gain. Cyproterone acetate can now be added to the list of
hormonal agents which has at least some activity in advanced
ovarian cancer, either due to its antiandrogenic action or
to its progestational activity. It may be of particular use in
those very elderly or frail patients for whom platinum-based
chemotherapy is felt inappropriate. Patients with long
disease-free intervals after first-line platinum chemotherapy
and with well or moderately differentiated tumours also
appear most likely to respond. Mild or even severe malaise
may complicate therapy in a minority of cases and careful
monitoring for thrombotic events should continue in light of
the two thrombotic events which occurred in this study,
albeit in the presence of significant malignant disease.
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